If you would like to ask our webinar guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund a question please submit them here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFeedback Regulatory News (FDBK)

Share Price Information for Feedback (FDBK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 80.00
Bid: 75.00
Ask: 85.00
Change: -2.50 (-3.03%)
Spread: 10.00 (13.333%)
Open: 82.50
High: 82.50
Low: 80.00
Prev. Close: 82.50
FDBK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Bleepa agreement with CVS Equine Division

16 Jul 2021 07:00

RNS Number : 4253F
Feedback PLC
16 July 2021
 

Prior to publication, the information contained within this announcement was deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 ("MAR") (which forms part of Domestic UK Law pursuant to the European Union (Withdrawal) Act 2018). With the publication of this announcement, this information is now considered to be in the public domain.

 

Feedback plc

 

Bleepa agreement with CVS Equine Division

 

· First private business win for Bleepa with one of UK's leading veterinary providers

· Contract covers 20 Equine surgeries and showcases new Bleepa capabilities

· Demonstrates Bleepa's value in new markets

 

London, 16 July 2021: Feedback plc (AIM: FDBK, "Feedback" or the "Company"), the specialist medical imaging technology company, today announces that CVS Group ("CVS"), one of the UK's leading providers of integrated veterinary services, has appointed Bleepa as its clinical communications platform for its Equine Division.

 

Following a successful pilot trial, CVS has adopted Bleepa for initial use in its Equine Division. Bleepa will be rolled-out across 20 equine specialist surgeries. The current agreement will result in increased Bleepa users, and importantly, provides scope for a broader relationship with CVS. Furthermore, this agreement highlights the scalability of Bleepa and the Company's ability to target non-NHS markets by tailoring the platform accordingly.

 

CVS has a clear vision to be the veterinary company people most want to work for by providing the best clinical care through great talent, facilities and equipment. Bleepa fits neatly into this drive to provide world-class animal care by providing their vets with its revolutionary clinical communications app. Bleepa enables vets in a field to securely connect with clinical colleagues for specialist advice and guidance whilst at the animal's side.

 

As part of the pilot, Feedback worked closely with the CVS team to adapt Bleepa, providing all the features needed for veterinary service, both within the surgery but also out in the field . Until now vets have not been able to easily acquire X-rays in a field and share these with colleagues. Bleepa developed an image push capability that enables X-rays to be securely pushed from the X-Ray machine over a cellular network to the Bleepa platform. The platform then makes these images available to specialists for immediate review and discussion, allowing the correct treatment guidance for the injured animal to be communicated to the vet and be provided at first visit. This capability means that images can now be taken in any location and can be instantly shared with specialist colleagues for timely advice and guidance. This technology has clear applications in both military and rural care delivery in developing countries.

 

Tom Oakley, CEO of Feedback, said:

 

"CVS is an important partner for Feedback and we are delighted to now be working with them officially. Their validation of our technology and expertise demonstrates the flexibility of Bleepa within new markets. By purchasing Bleepa, CVS have evidenced a real commitment to empower their vets by connecting them with specialist colleagues at the point of care, ultimately resulting in excellent animal care at the touch of a button, anywhere in the world."

 

Hattie Lawrence, Equine Director at CVS , said:

 

"We are delighted to be working with Feedback as we roll out this innovative technology across our Equine division. By introducing Bleepa, we will further enhance our clinical offering across the division and it will further enable us to give the best possible clinical care to our patients."

-Ends-

 

Enquiries:

 

Feedback plc

Tom Oakley, CEO

Lindsay Melvin, CFO

+44 (0) 20 3997 7634

IR@fbk.com

 

 

Allenby Capital Limited (Nominated Adviser)

David Worlidge / Asha Chotai

+44 (0)20 3328 5656

 

 

Walbrook PR Ltd

Tel: 020 7933 8780 or feedbackplc@walbrookpr.com

Paul McManus/Nick Rome/Nicholas Johnson

07980 541 893 or 07748 325 236 or 07884 664 686

 

 

Notes to editors

 

Feedback plc (AIM: FDBK) is a medical imaging technology business. Its core product, Bleepa, is a revolutionary medical imaging communications app, providing an easy-to-use, high quality tool to enable remote and secure communications between front-line clinicians and teams. Importantly, it is the only CE marked medical imaging communications platform on the NHSx clinical communications tools framework. Bleepa has unparalleled functionality for everyday practice and can be accessed from any internet-connected device, enabling control of patient cases when on the go.

 

Its highly scalable Software as a Service ("SaaS") based revenue model will provide increasing levels of visibility as the Company grows its customer base. With a growing distribution base and technology in place, the focus is on leveraging key relationships in order to drive sales both in the UK and internationally to all forms of care facilitators. As a fully certified medical device, Bleepa aims to disrupt the medical imaging communications market and, importantly, increase the accuracy and speed of diagnosis.

 

About CVS Group plc

 

CVS Group is one of the leading integrated veterinary service providers in the UK, the Netherlands and the Republic of Ireland. The business is focused on providing a high quality, people-led service to its customers, with outstanding and dedicated clinical teams and support staff at the core of its strategy.

 

The Group operates an integrated model with 528 practice sites across its three markets, including 9 specialist referral centres and 34 dedicated out-of-hours sites. Alongside Laboratories (providing diagnostic services to CVS and third parties), Crematoria (providing pet cremation and clinical waste disposal for its practices) and Animed Direct (the Group's online pharmacy and retail business).

 

The Group employs over 7,000 staff, including over 1,900 veterinary surgeons and over 2,300 nurses across its three territories.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCSFMFIIEFSELW
Date   Source Headline
25th Mar 20247:00 amRNSNew tuberculosis partnership in India
21st Mar 20247:00 amRNSFurther CDC Pilot Programme Secured
23rd Feb 202411:03 amRNSHolding(s) in Company
21st Feb 20247:00 amRNSHalf-year Report
21st Feb 20247:00 amRNSMedical Imaging Partnership Pilot Agreement
6th Feb 20247:00 amRNSNotice of Results & Investor Presentation
19th Dec 20237:01 amRNSHalf Year Trading Update
19th Dec 20237:00 amRNSAward of Pilot Funding
26th Oct 20232:24 pmRNSResult of AGM
25th Oct 20235:53 pmRNSDirector Dealing
27th Sep 202312:15 pmRNSNotice of AGM
12th Sep 20237:00 amRNSFinal Results
5th Sep 20237:00 amRNSNotice of Results & Investor Presentation
19th Jun 20237:00 amRNSYear End Trading Update
4th Apr 20237:00 amRNSBleepa-CareLocker contract extension with QVH
7th Feb 20237:00 amRNSHalf-year Report
3rd Feb 20233:56 pmRNSHolding(s) in Company
11th Jan 20237:00 amRNSNotice of Results, Analyst & Investor Presentation
22nd Dec 202212:08 pmRNSDirector/PDMR Shareholding: Correction
22nd Dec 20227:00 amRNSDirector/PDMR Shareholding
19th Dec 20227:00 amRNSHalf Year Trading Update
1st Nov 20223:36 pmRNSTotal Voting Rights
13th Oct 20222:55 pmRNSResult of AGM & Proposed Share Consolidation
29th Sep 20223:46 pmRNSHolding(s) in Company
20th Sep 20223:26 pmRNSNotice of AGM & Proposed Share Consolidation
20th Sep 20227:00 amRNSFinal Results
13th Sep 20227:00 amRNSNotice of Results & Investor Presentation
6th Sep 20227:00 amRNS12 month contract for Sussex CDC pilot extension
19th Jul 20227:00 amRNSContract Update
16th Jun 20227:00 amRNSYear End Trading Update
1st Jun 20227:00 amRNSTrading Update & Director Appointment
12th May 202212:44 pmRNSChange of Registered Office
12th Apr 20227:00 amRNSBleepa wins two NHS Contract Awards
31st Mar 20227:00 amRNSBleepa TB Screening Pilot Now Live in Odisha
23rd Feb 20227:00 amRNSGrant of Options and PDMR dealing
10th Feb 20227:00 amRNSInterim Results
31st Jan 20227:00 amRNSNotice of Results
13th Dec 20217:00 amRNSPartnership with Amazon Web Services
6th Dec 20213:06 pmRNSHolding(s) in Company
2nd Dec 202110:20 amRNSDirector/PDMR Shareholding
2nd Dec 20219:54 amRNSHolding(s) in Company
1st Dec 20214:27 pmRNSHolding(s) in Company
1st Dec 20213:09 pmRNSHolding(s) in Company
30th Nov 20214:05 pmRNSHolding(s) in Company
29th Nov 20211:36 pmRNSDirector Appointment
29th Nov 20211:35 pmRNSResults of AGM, Open Offer, Issue of Equity & TVR
18th Nov 202112:15 pmRNSHolding(s) in Company
16th Nov 20214:35 pmRNSPrice Monitoring Extension
2nd Nov 20211:52 pmRNSResult of Placing
2nd Nov 20217:01 amRNSProposed Placing and Open Offer

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.